Business Description
Neurogene Inc
NAICS : 541714
SIC : 2833
ISIN : US64135M1053
Total Employee Number:
131Description
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 25.49 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 51.4 | |||||
3-Year EPS without NRI Growth Rate | 51.8 | |||||
3-Year FCF Growth Rate | 54 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.05 | |||||
9-Day RSI | 75.96 | |||||
14-Day RSI | 72.44 | |||||
3-1 Month Momentum % | 39.53 | |||||
6-1 Month Momentum % | 57.48 | |||||
12-1 Month Momentum % | 32.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.08 | |||||
Quick Ratio | 13.08 | |||||
Cash Ratio | 12.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -119.7 | |||||
Shareholder Yield % | 0.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -36.99 | |||||
ROA % | -33.96 | |||||
ROIC % | -443.63 | |||||
3-Year ROIIC % | 1800.42 | |||||
ROC (Joel Greenblatt) % | -609.51 | |||||
ROCE % | -35.93 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.6 | |||||
Price-to-Tangible-Book | 2.6 | |||||
EV-to-EBIT | -5.63 | |||||
EV-to-Forward-EBIT | -0.65 | |||||
EV-to-EBITDA | -5.82 | |||||
EV-to-FCF | -6.67 | |||||
| Price-to-Net-Current-Asset-Value | 2.79 | |||||
| Price-to-Net-Cash | 2.83 | |||||
Earnings Yield (Greenblatt) % | -17.76 | |||||
FCF Yield % | -10.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neurogene Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.92 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 121.83 | ||
| 14-Day RSI | 72.44 | ||
| 14-Day ATR (€) | 1.618494 | ||
| 20-Day SMA (€) | 28.56 | ||
| 12-1 Month Momentum % | 32.67 | ||
| 52-Week Range (€) | 13.39 - 35.8 | ||
| Shares Outstanding (Mil) | 19.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurogene Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurogene Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 29 days | ||
| NGN-401 Phase 1/2 Clinical Data Update | 2026-06-29 08:00 | 26.00 (-1.52%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 14:40 | 22.80 (-2.56%) | ||
| General meeting for 2026 | 2026-06-03 09:00 | 22.20 (-5.13%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 11:30 | 23.80 (-5.56%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 25.80 (+0.00%) | ||
| Annual report for 2025 | 2026-03-24 | 16.42 (+1.80%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 16.42 (+1.80%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 13:40 | 18.60 (-1.12%) |
Show
Entries
Neurogene Inc Frequently Asked Questions
What is Neurogene Inc(STU:UU8)'s stock price today?
The current price of STU:UU8 is €34.80. The 52 week high of STU:UU8 is €35.80 and 52 week low is €13.39.
When is next earnings date of Neurogene Inc(STU:UU8)?
The next earnings date of Neurogene Inc(STU:UU8) is 2026-08-11 Est..
Does Neurogene Inc(STU:UU8) pay dividends? If so, how much?
Neurogene Inc(STU:UU8) does not pay dividend.
Press Release
Articles on Neurogene Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers